HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...

Related Keywords

Colorado ,United States ,Denver ,Orlando ,Florida ,Americans ,Kumar Budur ,Susan Hedstrom ,Luis Sanay ,Paige Rivard ,Foundation For Prader Willi Research ,Paragon Biosciences ,Research Symposium ,United States National Convention In Orlando ,Prnewswire Harmony Biosciences Holdings Inc ,Drug Administration ,Exchange Commission ,Prader Willi Syndrome Association United States ,Biosciences Holdings ,Annual Meeting ,Associated Professional Sleep Societies ,Epworth Sleepiness Scale ,Chief Medical Officer ,Executive Director ,Prader Willi Research ,Chief Executive Officer ,Prader Willi Syndrome Association ,National Convention ,Family Conference ,Primary Efficacy ,Safety Results ,Placebo Controlled Proof ,Signal Detection Study ,Serious Adverse Events ,Full Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Biosciences Media Contact ,Biosciences Investor Contact ,